Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches

Lina N Zaripova, Angela Midgley, Stephen E Christmas, Michael W Beresford, Eileen M Baildam, Rachel A Oldershaw, Lina N Zaripova, Angela Midgley, Stephen E Christmas, Michael W Beresford, Eileen M Baildam, Rachel A Oldershaw

Abstract

Juvenile idiopathic arthritis (JIA) is the most common paediatric rheumatological disorder and is classified by subtype according to International League of Associations for Rheumatology criteria. Depending on the number of joints affected, presence of extra-articular manifestations, systemic symptoms, serology and genetic factors, JIA is divided into oligoarticular, polyarticular, systemic, psoriatic, enthesitis-related and undifferentiated arthritis. This review provides an overview of advances in understanding of JIA pathogenesis focusing on aetiology, histopathology, immunological changes associated with disease activity, and best treatment options. Greater understanding of JIA as a collective of complex inflammatory diseases is discussed within the context of therapeutic interventions, including traditional non-biologic and up-to-date biologic disease-modifying anti-rheumatic drugs. Whilst the advent of advanced therapeutics has improved clinical outcomes, a considerable number of patients remain unresponsive to treatment, emphasising the need for further understanding of disease progression and remission to support stratification of patients to treatment pathways.

Keywords: Aetiology of juvenile idiopathic arthritis; Disease-modifying anti-rheumatic drug treatment; Juvenile idiopathic arthritis; Pathogenesis of juvenile idiopathic arthritis.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Schematic diagram showing the differences between the normal and JIA joint. The pathological process within the JIA synovial joint is characterised by uncontrolled proliferation of synoviocytes resulting in increased number of layers and thickening of the synovial membrane; rapid pathological angiogenesis; formation of pathological synovium, “pannus”, with uncontrolled growth and invasive properties; accumulation of granulocytes, macrophages, plasma cells, lymphocytes and the production of inflammatory mediators, provoking synovitis. Created with BioRender.com

References

    1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–778. doi: 10.1016/S0140-6736(07)60363-8.
    1. Macaubas C, Nguyen K, Milojevic D, Park JL, Mellins ED. Oligoarticular and polyarticular JIA: epidemiology and pathogenesis. Nat Rev Rheumatol. 2009;5(11):616–626. doi: 10.1038/nrrheum.2009.209.
    1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P, International League of Associations for Rheumatology International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.
    1. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138–2149. doi: 10.1016/S0140-6736(11)60244-4.
    1. Stoll ML, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. Curr Opin Rheumatol. 2011;23(5):437–443. doi: 10.1097/BOR.0b013e328348b278.
    1. Martini A. Systemic juvenile idiopathic arthritis. Autoimmun Rev. 2012;12(1):56–59. doi: 10.1016/j.autrev.2012.07.022.
    1. Ravelli A, Minoia F, Davi S, Horne A, Bovis F, Pistorio A, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism/American College of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative. Arthritis & rheumatology (Hoboken, NJ). 2016;68(3):566-76.
    1. Minoia F, Davi S, Horne A, Demirkaya E, Bovis F, Li C, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis & rheumatology (Hoboken, NJ). 2014;66(11):3160–9.
    1. Eng SW, Duong TT, Rosenberg AM, Morris Q, Yeung RS. The biologic basis of clinical heterogeneity in juvenile idiopathic arthritis. Arthritis & rheumatology (Hoboken, NJ). 2014;66(12):3463–75.
    1. Martini A, Ravelli A, Avcin T, Beresford MW, Burgos-Vargas R, Cuttica R, Ilowite NT, Khubchandani R, Laxer RM, Lovell DJ, Petty RE, Wallace CA, Wulffraat NM, Pistorio A, Ruperto N, for the Pediatric Rheumatology International Trials Organization (PRINTO) Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus. J Rheumatol. 2019;46(2):190–197. doi: 10.3899/jrheum.180168.
    1. Twilt M, Pradsgaard D, Spannow AH, Horlyck A, Heuck C, Herlin T. Joint cartilage thickness and automated determination of bone age and bone health in juvenile idiopathic arthritis. Pediatric rheumatology online journal. 2017;15(1):63. doi: 10.1186/s12969-017-0194-9.
    1. Swidrowska-Jaros J, Smolewska E. A fresh look at angiogenesis in juvenile idiopathic arthritis. Central-European journal of immunology. 2018;43(3):325–330. doi: 10.5114/ceji.2018.80052.
    1. Wojdas M, Dąbkowska K, Winsz-Szczotka K. Alterations of Extracellular Matrix Components in the Course of Juvenile Idiopathic Arthritis. Metabolites. 2021;11(3).
    1. Spelling P, Bonfá E, Caparbo VF, Pereira RM. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker? Scand J Rheumatol. 2008;37(6):439–444. doi: 10.1080/03009740802116224.
    1. Stagi S, Cavalli L, Signorini C, Bertini F, Cerinic MM, Brandi ML, Falcini F. Bone mass and quality in patients with juvenile idiopathic arthritis: longitudinal evaluation of bone-mass determinants by using dual-energy x-ray absorptiometry, peripheral quantitative computed tomography, and quantitative ultrasonography. Arthritis Res Ther. 2014;16(2):R83. doi: 10.1186/ar4525.
    1. Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7(7):416–426. doi: 10.1038/nrrheum.2011.68.
    1. Rigante D, Bosco A, Esposito S. The Etiology of Juvenile Idiopathic Arthritis2014.
    1. Mistry RR, Patro P, Agarwal V, Misra DP. Enthesitis-related arthritis: current perspectives. Open access rheumatology : research and reviews. 2019;11:19–31. doi: 10.2147/OARRR.S163677.
    1. Carlens C, Jacobsson L, Brandt L, Cnattingius S, Stephansson O, Askling J. Perinatal characteristics, early life infections and later risk of rheumatoid arthritis and juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68(7):1159–1164. doi: 10.1136/ard.2008.089342.
    1. Horton DB, Shenoi S. Review of environmental factors and juvenile idiopathic arthritis. Open Access Rheumatol. 2019;11:253–267. doi: 10.2147/OARRR.S165916.
    1. De Silvestri A, Capittini C, Poddighe D, Marseglia GL, Mascaretti L, Bevilacqua E, et al. HLA-DRB1 alleles and juvenile idiopathic arthritis: diagnostic clues emerging from a meta-analysis. Autoimmun Rev. 2017;16(12):1230–1236. doi: 10.1016/j.autrev.2017.10.007.
    1. Hollenbach JA, Thompson SD, Bugawan TL, Ryan M, Sudman M, Marion M, Langefeld CD, Thomson G, Erlich HA, Glass DN. Juvenile idiopathic arthritis and HLA class I and class II interactions and age-at-onset effects. Arthritis Rheum. 2010;62(6):1781–1791. doi: 10.1002/art.27424.
    1. Hersh AO, Prahalad S. Immunogenetics of juvenile idiopathic arthritis: a comprehensive review. J Autoimmun. 2015;64:113–124. doi: 10.1016/j.jaut.2015.08.002.
    1. Cobb JE, Hinks A, Thomson W. The genetics of juvenile idiopathic arthritis: current understanding and future prospects. Rheumatology (Oxford, England). 2014;53(4):592–9.
    1. Prahalad S, Glass DN. A comprehensive review of the genetics of juvenile idiopathic arthritis. Pediatric rheumatology online journal. 2008;6(1):11. doi: 10.1186/1546-0096-6-11.
    1. Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum. 2008;58(3):875–887. doi: 10.1002/art.23291.
    1. Prelog M, Schwarzenbrunner N, Sailer-Höck M, Kern H, Klein-Franke A, Ausserlechner MJ, Koppelstaetter C, Brunner A, Duftner C, Dejaco C, Strasak AM, Müller T, Zimmerhackl LB, Brunner J. Premature aging of the immune system in children with juvenile idiopathic arthritis. Arthritis Rheum. 2008;58(7):2153–2162. doi: 10.1002/art.23599.
    1. Arve-Butler S, Schmidt T, Mossberg A, Berthold E, Gullstrand B, Bengtsson AA, Kahn F, Kahn R. Synovial fluid neutrophils in oligoarticular juvenile idiopathic arthritis have an altered phenotype and impaired effector functions. Arthritis Res Ther. 2021;23(1):109. doi: 10.1186/s13075-021-02483-1.
    1. Schmidt T, Berthold E, Arve-Butler S, Gullstrand B, Mossberg A, Kahn F, Bengtsson AA, Månsson B, Kahn R. Children with oligoarticular juvenile idiopathic arthritis have skewed synovial monocyte polarization pattern with functional impairment-a distinct inflammatory pattern for oligoarticular juvenile arthritis. Arthritis Res Ther. 2020;22(1):186. doi: 10.1186/s13075-020-02279-9.
    1. Correll CK, Binstadt BA. Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis. Pediatr Res. 2014;75(1–2):176–183. doi: 10.1038/pr.2013.187.
    1. Machado SH, Xavier RM. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf. 2017;16(4):493–500. doi: 10.1080/14740338.2017.1303479.
    1. de Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis. 2007;66(5):589–598. doi: 10.1136/ard.2006.061853.
    1. Vastert SJ, Kuis W, Grom AA. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol. 2009;23(5):655–664. doi: 10.1016/j.berh.2009.08.003.
    1. Ishikawa S, Shimizu M, Inoue N, Mizuta M, Nakagishi Y, Yachie A. Interleukin-33 as a marker of disease activity in rheumatoid factor positive polyarticular juvenile idiopathic arthritis. Mod Rheumatol. 2017;27(4):609–613. doi: 10.1080/14397595.2016.1246118.
    1. Yasin S, Fall N, Brown RA, Henderlight M, Canna SW, Girard-Guyonvarc’h C, et al. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatology. 2019.
    1. Shimizu M, Inoue N, Mizuta M, Nakagishi Y, Yachie A. Serum leucine-rich α2-glycoprotein as a biomarker for monitoring disease activity in patients with systemic juvenile idiopathic arthritis. J Immunol Res. 2019;2019:3140204. doi: 10.1155/2019/3140204.
    1. Lee PY, Schulert GS, Canna SW, Huang Y, Sundel J, Li Y, Hoyt KJ, Blaustein RB, Wactor A, Do T, Halyabar O, Chang MH, Dedeoglu F, Case SM, Meidan E, Lo MS, Sundel RP, Richardson ET, Newburger JW, Hershfield MS, Son MB, Henderson LA, Nigrovic PA. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2020;79(2):225–231. doi: 10.1136/annrheumdis-2019-216030.
    1. Ip WKE, Hoshi N, Shouval DS, Snapper S, Medzhitov R. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science. 2017;356(6337):513–519. doi: 10.1126/science.aal3535.
    1. Feng M, Kang M, He F, Xiao Z, Liu Z, Yao H, Wu J. Plasma interleukin-37 is increased and inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells in systemic juvenile idiopathic arthritis patients. J Transl Med. 2018;16(1):277. doi: 10.1186/s12967-018-1655-8.
    1. Berntson L, Nordal E, Fasth A, Aalto K, Herlin T, Nielsen S, et al. Anti-type II collagen antibodies, anti-CCP, IgA RF and IgM RF are associated with joint damage, assessed eight years after onset of juvenile idiopathic arthritis (JIA) Pediatric rheumatology online journal. 2014;12(1):22. doi: 10.1186/1546-0096-12-22.
    1. Mahmud SA, Binstadt BA. Autoantibodies in the Pathogenesis, Diagnosis, and Prognosis of Juvenile Idiopathic Arthritis. Frontiers in immunology. 2019;9:3168-.
    1. Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED. Risk factors for development of uveitis differ between girls and boys with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62(6):1824–1828. doi: 10.1002/art.27416.
    1. Brunner J, Sitzmann FC. The diagnostic value of anti-cyclic citrullinated peptide (CCP) antibodies in children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2006;24(4):449–451.
    1. Gohar F, Anink J, Moncrieffe H, Van Suijlekom-Smit LWA, Prince FHM, van Rossum MAJ, et al. S100A12 is associated with response to therapy in juvenile idiopathic arthritis. J Rheumatol. 2018;45(4):547–554. doi: 10.3899/jrheum.170438.
    1. Aljaberi N, Tronconi E, Schulert G, Grom AA, Lovell DJ, Huggins JL, Henrickson M, Brunner HI. The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. Pediatric rheumatology online journal. 2020;18(1):7. doi: 10.1186/s12969-020-0398-2.
    1. Cimaz R. Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev. 2016;15(9):931–934. doi: 10.1016/j.autrev.2016.07.004.
    1. Lee JJY, Schneider R. Systemic juvenile idiopathic arthritis. Pediatr Clin N Am. 2018;65(4):691–709. doi: 10.1016/j.pcl.2018.04.005.
    1. Ringold S, Weiss PF, Beukelman T, Dewitt EM, Ilowite NT, Kimura Y, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis care & research. 2013;65(10):1551–1563. doi: 10.1002/acr.22087.
    1. Klein A, Kaul I, Foeldvari I, Ganser G, Urban A, Horneff G. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German methotrexate registry. Arthritis care & research. 2012;64(9):1349–1356. doi: 10.1002/acr.21697.
    1. Ferrara G, Mastrangelo G, Barone P, La Torre F, Martino S, Pappagallo G, et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol. 2018;16(1):46. doi: 10.1186/s12969-018-0255-8.
    1. Papadopoulou C, Kostik M, Böhm M, Nieto-Gonzalez JC, Gonzalez-Fernandez MI, Pistorio A, Martini A, Ravelli A. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis. J Pediatr. 2013;163(3):879–884. doi: 10.1016/j.jpeds.2013.03.047.
    1. Ayaz NA, Karadag SG, Cakmak F, Cakan M, Tanatar A, Sonmez HE. Leflunomide treatment in juvenile idiopathic arthritis. Rheumatol Int. 2019;39(9):1615–1619. doi: 10.1007/s00296-019-04385-7.
    1. Blazina Š, Markelj G, Avramovič MZ, Toplak N, Avčin T. Management of Juvenile Idiopathic Arthritis: a clinical guide. Paediatric drugs. 2016;18(6):397–412. doi: 10.1007/s40272-016-0186-0.
    1. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatric rheumatology online journal. 2014;12(1):13. doi: 10.1186/1546-0096-12-13.
    1. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric rheumatology collaborative study group. N Engl J Med. 2000;342(11):763–769. doi: 10.1056/NEJM200003163421103.
    1. Vanoni F, Minoia F, Malattia C. Biologics in juvenile idiopathic arthritis: a narrative review. Eur J Pediatr. 2017;176(9):1147–1153. doi: 10.1007/s00431-017-2960-6.
    1. Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, Silverman ED, Balogh Z, Henrickson M, Davidson J, Foeldvari I, Imundo L, Simonini G, Oppermann J, Xu S, Shen YK, Visvanathan S, Fasanmade A, Mendelsohn A, Martini A, Giannini EH, Paediatric Rheumatology INternational Trials Organization (PRINTO) Pediatric Rheumatology Collaborative Study Group (PRCSG) Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis. 2010;69(4):718–722. doi: 10.1136/ard.2009.100354.
    1. Balevic SJ, Rabinovich CE. Profile of adalimumab and its potential in the treatment of uveitis. Drug Des Devel Ther. 2016;10:2997–3003. doi: 10.2147/DDDT.S94188.
    1. Lovell DJ, Ruperto N, Mouy R, Paz E, Rubio-Perez N, Silva CA, et al. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis & rheumatology (Hoboken, NJ). 2015;67(10):2759–70.
    1. Ramanan AV, Dick AD, Guly C, McKay A, Jones AP, Hardwick B, Lee RWJ, Smyth M, Jaki T, Beresford MW, APTITUDE Trial Management Group Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. The Lancet Rheumatology. 2020;2(3):e135–ee41. doi: 10.1016/S2665-9913(20)30008-4.
    1. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545–555. doi: 10.1002/art.30128.
    1. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201(9):1479–1486. doi: 10.1084/jem.20050473.
    1. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, Richer O, Chaussabel D, Mogenet A, Banchereau J, Treluyer JM, Landais P, Pascual V. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial) Ann Rheum Dis. 2011;70(5):747–754. doi: 10.1136/ard.2010.134254.
    1. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, Horneff G, Kasapcopur O, Schneider R, Anton J, Barash J, Berner R, Corona F, Cuttica R, Fouillet-desjonqueres M, Fischbach M, Foster HE, Foell D, Radominski SC, Ramanan AV, Trauzeddel R, Unsal E, Levy J, Vritzali E, Martini A, Lovell DJ, On behalf of the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis. 2018;77(12):1710–1719. doi: 10.1136/annrheumdis-2018-213150.
    1. Ruperto N, Martini A. Current and future perspectives in the management of juvenile idiopathic arthritis. The Lancet Child & adolescent health. 2018;2(5):360–370. doi: 10.1016/S2352-4642(18)30034-8.
    1. Giancane G, Minoia F, Davì S, Bracciolini G, Consolaro A, Ravelli A. IL-1 inhibition in systemic juvenile idiopathic arthritis. Front Pharmacol. 2016;7:467. doi: 10.3389/fphar.2016.00467.
    1. Ilowite NT, Prather K, Lokhnygina Y, Schanberg LE, Elder M, Milojevic D, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis & rheumatology (Hoboken, NJ). 2014;66(9):2570–9.
    1. Martini A. Are there new targets for juvenile idiopathic arthritis? Semin Arthritis Rheum. 2019;49(3s):S11–Ss3. doi: 10.1016/j.semarthrit.2019.09.017.
    1. Krei JM, Møller HJ, Larsen JB. The role of interleukin-18 in the diagnosis and monitoring of hemophagocytic lymphohistiocytosis/macrophage activation syndrome - a systematic review. Clin Exp Immunol. 2021;203(2):174–182. doi: 10.1111/cei.13543.
    1. Sakamoto AP, Pinheiro MM, Barbosa CM, Fraga MM, Len CA, Terreri MT. Rituximab use in young adults diagnosed with juvenile idiopathic arthritis unresponsive to conventional treatment: report of 6 cases. Rev Bras Reumatol. 2015;55(6):536–541. doi: 10.1016/j.rbr.2014.12.015.
    1. Benedetti FD, Brogan P, Grom A, Quartier P, Schneider R, Graaf KD, et al. OP0204 EMAPALUMAB, AN INTERFERON GAMMA (IFN-Y)-BLOCKING MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA). Annals of the Rheumatic Diseases. 2019;78(Suppl 2):178-.
    1. Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. Ann Rheum Dis. 2018;77(6):840–847. doi: 10.1136/annrheumdis-2017-212608.
    1. Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, McInnes I, Pope JE, van der Heijde D, Stoffer-Marx M, Takeuchi T, Trauner M, Winthrop KL, de Wit M, Aletaha D, Baraliakos X, Boehncke WH, Emery P, Isaacs JD, Kremer J, Lee EB, Maksymowych WP, Voshaar M, Tam LS, Tanaka Y, van den Bosch F, Westhovens R, Xavier R, Smolen JS. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80(1):71–87. doi: 10.1136/annrheumdis-2020-218398.
    1. Huang Z, Lee PY, Yao X, Zheng S, Li T. Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis. Pediatrics. 2019;143(5).
    1. Miserocchi E, Giuffrè C, Cornalba M, Pontikaki I, Cimaz R. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39(3):847–851. doi: 10.1007/s10067-019-04875-w.
    1. Ruperto N, Synoverska O, Ting T, Abud-Mendoza C, Spindler A, Vyzhga Y, et al. OP0291 TOFACITINIB for the treatment of POLYARTICULAR course juvenile idiopathic arthritis: results of a phase 3, randomised, double-blind, placebo-controlled withdrawal study. Ann Rheum Dis. 2020;79(Suppl 1):180–181.
    1. Welzel T, Winskill C, Zhang N, Woerner A, Pfister M. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials. Pediatric rheumatology online journal. 2021;19(1):46. doi: 10.1186/s12969-021-00514-4.
    1. Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS, Szer IS, Ringold S, Brunner HI, Schanberg LE, Sundel RP, Milojevic D, Punaro MG, Chira P, Gottlieb BS, Higgins GC, Ilowite NT, Kimura Y, Hamilton S, Johnson A, Huang B, Lovell DJ, for the Childhood Arthritis and Rheumatology Research Alliance Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64(6):2012–2021. doi: 10.1002/art.34343.
    1. Blazina Š, Markelj G, Avramovič MZ, Toplak N, Avčin T. Management of Juvenile Idiopathic Arthritis: a clinical guide. Pediatr Drugs. 2016;18(6):397–412. doi: 10.1007/s40272-016-0186-0.
    1. Minden K. Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res. 2009;72(Suppl 1):20–25. doi: 10.1159/000229759.
    1. Selvaag AM, Aulie HA, Lilleby V, Flato B. Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis. Ann Rheum Dis. 2016;75(1):190–195. doi: 10.1136/annrheumdis-2014-206034.
    1. Momah T, Ray L. Juvenile idiopathic arthritis: old disease, new tactics. J Fam Pract. 2019;68(2):E8–e13.
    1. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol. 2002;29(9):1989–1999.
    1. Anink J, Prince FH, Dijkstra M, Otten MH, Twilt M, ten Cate R, et al. Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children Register. Rheumatology (Oxford, England). 2015;54(11):1964–9.
    1. Barisic Kutija M, Peric S, Knezevic J, Juratovac Z, Vukojevic N. Complication and prognosis of juvenile idiopathic arthritis associated uveitis in the era of modern immunomodulatory treatment. Psychiatr Danub. 2019;31(Suppl 1):44–49.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa